METTL3 and nonpapillary renal cell carcinoma: Therapeutic strategies targeting METTL3—including pharmacologic inhibition (e.g., Erianin, STM2457) and combination regimens with mTOR or immune checkpoint inhibitors—exploit its role in ccRCC’s molecular vulnerabilities.